Madrigal Pharmaceuticals, Inc. engages in the development and commercialization of innovative therapeutic candidates for the treatment of cardiovascular, metabolic, and liver diseases. Its lead product, MGL-3196, is used for the treatment of non-alcoholic steatohepatitis and familial hypercholesterolemia. The company was founded by Rebecca Taub and Edward Chiang on March 2000 and is headquartered in West Conshohocken, PA.
相关临床试验
37
18 进行中
药物批准
2
批准总数
监管机构
1
监管机构数
成立时间
2016
进行中（未招募）
18
48.6%
已完成
14
37.8%
招募中
5
13.5%
- The global NASH treatment market is projected to grow from USD 8.75 billion in 2025 to USD 46.87 billion by 2032, expanding at a CAGR of 27.1%. - Madrigal's Rezdiffra, approved in March 2024, created the first dedicated liver-directed prescription pathway for noncirrhotic NASH with moderate-to-advanced fibrosis. - Novo Nordisk's Wegovy gained FDA approval in August 2025 for MASH with F2–F3 fibrosis, connecting liver treatment to established obesity and diabetes care networks. - Late-stage pipeline candidates from Eli Lilly, Akero Therapeutics, 89bio, Inventiva, and Boehringer Ingelheim could create a multi-mechanism, segmented treatment market.
- The 2026 ADA Standards of Care formally reposition cardiovascular and kidney risk reduction as coequal priorities alongside glucose lowering, no longer treating them as secondary goals. - GLP-1 receptor agonists and SGLT-2 inhibitors are now explicitly recommended for consideration from the time of type 2 diabetes diagnosis as disease-modifying therapies. - The holistic care framework expands beyond cardiovascular and kidney disease to include fatty liver disease, cognitive dysfunction, and osteoarthritis, with finerenone recognized for heart failure outcomes. - Updated blood pressure guidance encourages achieving systolic blood pressure below 120 mmHg in appropriate patients with diabetes where feasible.
- Exelixis surged 5.0% to $50.99 on Wednesday amid a broad biotechnology rally, with no company-specific catalysts driving the move. - PTC Therapeutics jumped 5.1% to $89.80 on Tuesday, riding the same sector-wide momentum alongside peers posting gains of 4.0% to 6.9%. - Coordinated buying across multiple biotech names suggests institutional investors are rotating into the sector, reflecting improved risk appetite toward growth-oriented healthcare. - Trading volumes remained moderate, with Exelixis at 1.1M shares and PTC Therapeutics at 823,046 shares, indicating measured rather than explosive positioning.
- Rezdiffra significantly improved atherogenic lipid profiles including LDL-C, ApoB and Lp(a) in MASH patients, with 37.5% of statin-treated patients achieving clinically meaningful Lp(a) reductions below 50mg/dL. - In patients with compensated MASH cirrhosis, Rezdiffra treatment reduced high-risk classification for portal hypertension from 75% to 54.5% over two years using the ANTICIPATE-NASH risk score. - Real-world evidence demonstrated that 49% of patients achieved ≥25% reduction in liver stiffness over nine months, with sustained improvements in liver enzymes and cardiometabolic parameters. - Multiple analyses support Rezdiffra's potential as foundational MASH therapy, addressing both liver disease progression and cardiovascular risk factors in routine clinical practice.
- Galmed Pharmaceuticals has received a new use patent in South Korea for the combination of Aramchol and Madrigal's Rezdiffra (resmetirom) to treat metabolic dysfunction-associated steatohepatitis (MASH) and liver fibrosis. - The patent extends Aramchol's global intellectual property protection until July 2042, building on previous patents granted in the United States, Europe, Canada, and other jurisdictions. - Aramchol is positioned as a first-in-class, Phase 3-ready drug candidate with demonstrated robust fibrosis improvement in advanced clinical studies and excellent safety profile. - The patent grant comes as the MASH treatment field shifts toward combination therapies due to limited efficacy of monotherapies in addressing this complex liver disease.
- DelveInsight's 2025 analysis reveals over 30 companies are actively developing more than 30 therapeutic candidates for liver cirrhosis, driven by rising global prevalence of liver diseases, particularly NAFLD associated with obesity and metabolic syndrome. - Sagimet Biosciences received FDA Breakthrough Therapy and Fast Track designations for denifanstat in February 2025, while Madrigal Pharmaceuticals plans to launch REZDIFFRA in Europe starting with Germany in the second half of 2025. - Multiple Phase III trials are progressing, including Akero Therapeutics' completed enrollment in the SYNCHRONY Real-World study with results expected in the first half of 2026, and ongoing ENLIGHTEN trials for MASH cirrhosis. - Key investigational therapies advancing through clinical development include Volixibat, TVB-2640, belapectin, RTX001, and LPCN 1148, representing diverse mechanisms of action from sodium-bile acid cotransporter inhibition to macrophage cell therapy.
- A secondary analysis of the MAESTRO-NASH phase 3 trial demonstrates that resmetirom's efficacy in treating metabolic-dysfunction associated steatohepatitis (MASH) remains consistent regardless of concurrent GLP-1 receptor agonist or SGLT2 inhibitor therapy. - Patients achieving at least 5% weight loss during treatment experienced significantly enhanced MASH resolution rates, with 56.6% response in the resmetirom 100 mg group compared to 33.8% in those with minimal weight loss. - The findings support the safe and effective combination of resmetirom with commonly used diabetes medications, providing important guidance for treating MASH patients with type 2 diabetes. - Resmetirom's liver-targeted mechanism remains independent of weight loss effects, but modest weight reduction provides additive therapeutic benefits for both histological and imaging outcomes.
- Singapore-based HistoIndex has launched FibroSIGHT Plus, an AI-based laboratory developed test that provides automated quantitative analysis of fibrosis in MASH patients using proprietary qFibrosis algorithm. - The new LDT utilizes stain-free Second Harmonic Generation imaging to quantify fibrosis on a continuous scale rather than discrete categories, enabling more precise disease characterization and monitoring. - The technology addresses the growing MASH market, which GlobalData projects will reach $25.7 billion by 2032 across seven major markets, following the first FDA-approved treatment in 2024. - Clinical experts highlight the test's ability to detect incremental fibrosis changes with high precision, supporting earlier and more targeted interventions for MASH patients.
- DelveInsight's 2025 pipeline analysis reveals over 30 companies developing 30+ liver cirrhosis therapies, with promising candidates like Rezdiffra, efruxifermin, and belapectin showing significant clinical progress. - Madrigal Pharmaceuticals' Rezdiffra demonstrated reduced liver scarring in compensated cirrhosis patients in Phase 3 MAESTRO-NAFLD-1 trial data, while Akero Therapeutics reported preliminary results from its Phase IIb SYMMETRY study of efruxifermin. - The liver cirrhosis treatment market is experiencing robust growth driven by rising global prevalence of liver diseases, particularly NAFLD, fueled by lifestyle factors including obesity and metabolic syndrome. - Key pipeline therapies span diverse mechanisms including sodium-bile acid cotransporter inhibitors, regulatory T-lymphocyte stimulants, and Wnt signaling pathway inhibitors across oral, intravenous, and subcutaneous administration routes.
- Neurocrine Biosciences, Madrigal Pharmaceuticals, and Vanda Therapeutics provided investors with key updates on their recent drug launches during Q1 earnings calls. - Cytokinetics announced an FDA review extension for aficamten, their investigational cardiac myosin inhibitor, potentially impacting their timeline for market entry. - The Q1 earnings season highlights significant catalysts across the biopharma sector as companies navigate regulatory pathways and initial commercialization challenges.
